Idiotype-specific neonatal suppression of phosphorylcholine-responsive B cells

Area of Science:

• Immunology
• B cell development
• Clonotype suppression

Background:

• Neonatal immune tolerance mechanisms are crucial for preventing autoimmunity.
• Anti-idiotypic antibodies can modulate immune responses by targeting B cell receptors.

Purpose of the Study:

• To investigate the impact of neonatal anti-idiotypic suppression on T15 clonotype B cell expression.
• To determine the factors influencing the efficacy and specificity of this suppression.

Main Methods:

• Neonatal injection of allogeneic anti-T15 idiotype serum in mice.
• Analysis of B cell repertoire at the clonal precursor level.
• Administration of T15 myeloma protein to assess reversibility of suppression.

Main Results:

• Neonatal anti-T15 idiotype serum injection led to near-complete elimination of T15 clonotype B cells for up to four months.
• Suppression efficacy correlated with anti-idiotypic antibody dose and timing of administration (most effective within the first week of life).
• Adult mice showed no suppression, suggesting immature B cells are the primary target; however, suppression in young mice was reversible with T15 myeloma protein.

Conclusions:

• Neonatal anti-idiotypic suppression is a potent method for eliminating specific B cell clonotypes, particularly immature ones.
• The presence of idiotype in adult serum may confer resistance to suppression.
• Anti-T15 suppression does not affect other B cell clonotypes, even those sharing antigen-binding site determinants, indicating high specificity.